このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Vitrolife マネジメント

マネジメント基準チェック /24

Vitrolife'sの CEO はBronwyn Brophy O´Connorで、 Aug2023年に任命され、の在任期間は 1 年未満です。の年間総報酬はSEK 7.44Mで、 74.5%給与と25.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.014%を直接所有しており、その価値はSEK 3.40M 。経営陣と取締役会の平均在任期間はそれぞれ1.1年と6.4年です。

主要情報

Bronwyn Brophy O´Connor

最高経営責任者

kr7.4m

報酬総額

CEO給与比率	74.5%
CEO在任期間	less than a year
CEOの所有権	0.01%
経営陣の平均在職期間	1.1yrs
取締役会の平均在任期間	6.4yrs

経営陣の近況

Recent updates

Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt

Apr 03

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Mar 07

Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now

Feb 05

An Intrinsic Calculation For Vitrolife AB (publ) (STO:VITR) Suggests It's 27% Undervalued

Aug 25

Vitrolife (STO:VITR) Could Easily Take On More Debt

Aug 03

Are Vitrolife AB (publ) (STO:VITR) Investors Paying Above The Intrinsic Value?

May 26

Is Vitrolife (STO:VITR) A Risky Investment?

Jan 23

Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly

Oct 18

Calculating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Sep 09

Is Vitrolife (STO:VITR) A Risky Investment?

Jul 07

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

May 26

Vitrolife (STO:VITR) Seems To Use Debt Rather Sparingly

Mar 31

Estimating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Feb 07

There May Be Reason For Hope In Vitrolife's (STO:VITR) Disappointing Earnings

Apr 29

Is Vitrolife AB (publ)'s (STO:VITR) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Mar 16

Who Has Been Selling Vitrolife AB (publ) (STO:VITR) Shares?

Jan 22

Vitrolife (STO:VITR) Shareholders Have Enjoyed An Impressive 289% Share Price Gain

Dec 18

CEO報酬分析

Vitrolife の収益と比較して、Bronwyn Brophy O´Connor の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-kr4b
Dec 31 2023	kr7m	kr6m	-kr4b

報酬と市場: Bronwynの総報酬 ($USD 716.00K ) は、 Swedish市場 ($USD 772.88K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Bronwynの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Bronwyn Brophy O´Connor (50 yo)

less than a year

在職期間

kr7,439,000

報酬

Ms. Bronwyn Brophy O´Connor is President and Chief Executive Officer at Vitrolife AB (publ) since joining from August 01, 2023. She has an impressive track record as a leader of global Life science and Med...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Bronwyn Brophy O´Connor	CEO & President	less than a year	kr7.44m	0.014% SEK 3.4m
Patrik Tolf	Chief Financial Officer	2.4yrs	データなし	0.0096% SEK 2.3m
Claus Bisgaard	Senior Vice President of Technologies	no data	データなし	0.00028% SEK 67.0k
Guillermo Ferrando	Vice President Strategy & Corporate development	1.4yrs	データなし	データなし
Olivia Natens	Senior Vice President of Sales & Marketing	less than a year	データなし	データなし
Frank Pettersson	Acting Senior Vice President of HR & Sustainability	no data	データなし	0.0013% SEK 313.4k
Rickard Ericsson	Senior Vice President of Consumables	less than a year	データなし	0.0061% SEK 1.5m
Ricardo Capella	Senior Vice President Genetic Services	2.4yrs	データなし	0.0044% SEK 1.1m

1.1yrs

平均在職期間

53.5yo

平均年齢

経験豊富な経営陣: VITRの経営陣は経験豊富とはみなされません ( 1.1年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Henrik Blomquist	Director	5.1yrs	kr883.00k	0.0081% SEK 1.9m
Jon Sigurdsson	Chairman of the Board	9.4yrs	kr16.30m	0.022% SEK 5.4m
Lars Holmqvist	Independent Director	6.4yrs	kr450.00k	データなし
Pia Marions	Independent Director	11.2yrs	kr500.00k	0.0037% SEK 882.8k
Karen Soerensen	Independent Director	4yrs	kr500.00k	データなし

6.4yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: VITRの取締役会は経験豊富であると考えられます ( 6.4年の平均在任期間)。

Vitrolife マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Director recently bought kr1.6m worth of stock

Vitrolife AB (publ) Announces Election Committee Appointments

Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice President

Insufficient new directors

Vitrolife AB Announces Board Changes

Chief Financial Officer recently bought kr335k worth of stock

Recent updates

Vitrolife AB (publ) (OM:VITR) acquired Stb Zorg B.V.

Director recently bought kr1.6m worth of stock

Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million.

Vitrolife AB (Publ) Approves Dividend for the Financial Year 2023

Upcoming dividend of kr1.00 per share

First quarter 2024 earnings released: EPS: kr0.85 (vs kr0.74 in 1Q 2023)

Now 22% undervalued

Dividend increased to kr1.00

Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now

Full year 2023 earnings: EPS misses analyst expectations

Vitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023

Vitrolife AB (publ)'s (STO:VITR) Share Price Matching Investor Opinion

Here's Why We Think Vitrolife (STO:VITR) Is Well Worth Watching

Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)

Is Vitrolife (STO:VITR) A Risky Investment?

Investor sentiment improves as stock rises 21%

Price target decreased by 8.9% to kr257

Third quarter 2023 earnings released: EPS: kr0.90 (vs kr0.80 in 3Q 2022)

Vitrolife AB (publ) Announces Election Committee Appointments

An Intrinsic Calculation For Vitrolife AB (publ) (STO:VITR) Suggests It's 27% Undervalued

Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice President

Insufficient new directors

Vitrolife (STO:VITR) Could Easily Take On More Debt

Vitrolife AB Announces Board Changes

Chief Financial Officer recently bought kr335k worth of stock

Consensus EPS estimates fall by 16%

Price target decreased by 7.4% to kr292

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 15%

Vitrolife AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

Are Vitrolife AB (publ) (STO:VITR) Investors Paying Above The Intrinsic Value?

Chief Financial Officer recently bought kr535k worth of stock

Chief Financial Officer recently bought kr535k worth of stock

Upcoming dividend of kr0.85 per share at 0.4% yield

Full year 2022 earnings: EPS misses analyst expectations

Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021)

Vitrolife AB (publ) Proposes Dividend for 2022

Vitrolife AB (publ) Announces Executive Changes

Is Vitrolife (STO:VITR) A Risky Investment?

Price target decreased to kr260

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Vitrolife AB (publ) to Report First Half, 2023 Results on Jul 14, 2023

Investor sentiment improved over the past week

Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly

Vitrolife AB (publ) Announces Election Committee Appointments

Price target decreased to kr307

Now 30% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Vitrolife AB (Publ) Announces Retirement of Thomas Axelsson as CEO

Calculating The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Vitrolife AB (publ), Annual General Meeting, Apr 27, 2023

Is Vitrolife (STO:VITR) A Risky Investment?

A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)

Chief Financial Officer recently bought kr496k worth of stock

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to kr448

Upcoming dividend of kr0.80 per share

Vitrolife (STO:VITR) Seems To Use Debt Rather Sparingly

Vitrolife AB (Publ) Proposes Dividend

Consensus forecasts updated

Price target decreased to kr498

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Vitrolife AB (Publ) Proposes Dividend

マネジメント基準チェック /24